Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.
| Revenue (Most Recent Fiscal Year) | $189.76M |
| Net Income (Most Recent Fiscal Year) | $-196.54M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 26.62 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 47.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -92.89% |
| Net Margin (Trailing 12 Months) | -93.33% |
| Return on Equity (Trailing 12 Months) | -203.25% |
| Return on Assets (Trailing 12 Months) | -44.99% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.17 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.89 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.96 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.83 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 68.53M |
| Free Float | 64.49M |
| Market Capitalization | $5.78B |
| Average Volume (Last 20 Days) | 0.66M |
| Beta (Past 60 Months) | 1.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.90% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |